Praxis Precision Medicines Hits Q2 2026 Milestones: FDA Green Lights, Breakthrough Designations and $1.4 B Cash Reserve
Praxis Precision Medicines reports Q2 2026 highlights: FDA mid‑cycle success, two Breakthrough Therapy designations, and strong cash runway—propelling CNS drug launch.
- PRAXIS PRECISION MEDICINES I
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read
